A practical reference on Nicotinamide mononucleotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
| Property | Value | Notes |
|---|---|---|
| Systematic class | Pyridine nucleotide | Contains nicotinamide, ribose, and phosphate |
| Common form | beta-NMN | Anomeric configuration relevant to enzyme recognition |
| Molecular formula | C11H15N2O8P | As the free acid |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | Commonly associated with beta-D-NMN |
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
== See also == Substituted methylenedioxyphenethylamine I Feel Love: MDMA and the Quest for Connection in a Fractured World Lykos Therapeutics Multidisciplinary Association for Psychedelic Studies (MAPS) Non-racemic MDMA and (R)-MDMA Carina Leveriza-Franz
=== Carboplatin === Pemetrexed is also recommended in combination with carboplatin and pembrolizumab for the first-line treatment of advanced non-small cell lung cancer. However, the relative efficacy or toxicity of pemetrexed-cisplatin versus pemetrexed-carboplatin has not been established beyond what is generally thought about cisplatin or carboplatin doublet drug therapy.
=== Post B.P.C. Mining === In March 1981, the Phosphate Mining Company of Christmas Island (PMCI), a company established and controlled by the Australian Government, took over mining operations This arrangement lasted until December 1987 when the company was disbanded. The mining operation was then taken over by the Union of Christmas Island Workers.
Sources: en.wikipedia.org
Late-20th-century DNA sequencing changed lichen systematics, as it did the rest of biology. By the 1990s gene-specific sequencing (e.g., nuclear ribosomal DNA) was accessible, and lichenologists used it to probe deep relationships and test classical schemes. Initial studies centred on nuclear small-subunit rDNA (nuSSU), a slowly evolving gene found in all fungi. Andrea Gargas and co-workers (1995) compared nuSSU sequences from many fungi, including several lichens. Their data supplied the first clear evidence that lichenization arose independently multiple times. Lichen-forming fungi in the sample occupied at least five separate branches of the fungal tree. Three origins lay in the Basidiomycota—for example Omphalina and Multiclavula (mushroom-forming, algal partners) and Dictyonema (cyanobacterial partner). Two further origins occurred in the Ascomycota: one in the large ascolichen clade now placed in Lecanoromycetes, the other in Arthoniomycetes (e.g., some crustose Arthonia species). The pattern contradicted the view that lichens form a single natural group. Instead, 'lichen' is best seen as a functional category—an ecological strategy adopted by disparate fungal lineages. The study suggested that lichen-forming fungi evolved from saprotrophic or parasitic ancestors, not from a single ancestral lichen; some lineages later lost the symbiosis. In other words, the ability to form a lichen could evolve from a non-lichen state multiple times, and perhaps even be lost (as some primarily lichen-forming groups also include non-lichenized fungi).
Leukolike vectors are a type of nanoparticles made of nanoporous silicon encapsulated by extracted native leukocyte membranes. These particles were among the first artificial white blood cells to be studied as a proof of concept of using cellular membranes to prolong circulation of nanoparticles throughout the blood. Studies have shown that leukolike vectors have a specific advantage in chemotherapy drug delivery to cancer. This is because leukolike vectors specifically have the potential to bind to tumor endothelium.
Like the lanthanides, the actinides form a family of elements with similar properties. Within the actinides, there are two overlapping groups: transuranium elements, which follow uranium in the periodic table, and transplutonium elements, which follow plutonium. Compared to the lanthanides, which (except for promethium) are found in nature in appreciable quantities, most actinides are rare. Most do not occur in nature, and of those that do, only thorium and uranium do so in more than trace quantities. The most abundant or easily synthesized actinides are uranium and thorium, followed by plutonium, americium, actinium, protactinium, neptunium, and curium. The existence of transuranium elements was suggested in 1934 by Enrico Fermi, based on his experiments. However, even though four actinides were known by that time, it was not yet understood that they formed a family similar to lanthanides. The prevailing view that dominated early research into transuranics was that they were regular elements in the 7th period, with thorium, protactinium and uranium corresponding to 6th-period hafnium, tantalum and tungsten, respectively. Synthesis of transuranics gradually undermined this point of view. By 1944, an observation that curium failed to exhibit oxidation states above 4 (whereas its supposed 6th period homolog, platinum, can reach oxidation state of 6) prompted Glenn Seaborg to formulate an "actinide hypothesis".
Sources: en.wikipedia.org
Zebrafish Amphipod Hyalella curvispina, the earthworm Eisenia Andrei Tilapia Oreochromis mossambicus Frog Pseudacris regilla and salamander Ambystoma gracile Toad Rhinella arenarum Rainbow trout oncorhynchus mykiss Comparison between the toad Rhinella arenarum and the rainbow trout oncorhynchus mykiss Comparison between fish Mysidopsis bahia and Cyprinodon variegatus
== See also == Advanced Landing Ground – a type of semi-permanent bases in Kent, France, Belgium, Netherlands and occupied Germany Air Ministry Experimental Station Chain Home – radar defence system developed during the Second World War Class A airfield – airfields constructed to Air Ministry specifications during the Second World War List of Battle of Britain airfields List of North African airfields during World War II List of Royal Air Force stations, current MoD and RAF stations List of Royal Air Force Satellite Landing Grounds List of V Bomber dispersal bases
It is a member of the small pentraxins family (also known as short pentraxins). The polypeptide encoded by this gene has 224 amino acids. The full-length polypeptide is not present in the body in significant quantities due to signal peptide, which is removed by signal peptidase before translation is completed. The complete protein, composed of five monomers, has a total mass of approximately 120,000 Da. In serum, it assembles into stable pentameric structure with a discoid shape.
Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation. It is also used for hereditary angioedema. It is taken either by mouth, injection into a vein, or by intramuscular injection. Tranexamic acid is a synthetic analog of the amino acid lysine. It serves as an antifibrinolytic by reversibly binding four to five lysine receptor sites on plasminogen. This decreases the conversion of plasminogen to plasmin, preventing fibrin degradation and preserving the framework of fibrin's matrix structure. Tranexamic acid has roughly eight times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid. Tranexamic acid also directly inhibits the activity of plasmin with weak potency (IC50 = 87 mM), and it can block the active-site of urokinase plasminogen activator (uPA) with high specificity (Ki = 2 mM), one of the highest among all the serine proteases. Side effects are rare; they include changes in color vision, seizures, blood clots, and allergic reactions. Tranexamic acid appears to be safe for use during pregnancy and breastfeeding. Tranexamic acid was first made in 1962 by Japanese researchers Shosuke and Utako Okamoto. It is on the World Health Organization's List of Essential Medicines. Tranexamic acid is available as a generic drug.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.
NMN is a direct precursor in the salvage pathway that produces NAD+. Enzymes called NMN adenylyltransferases convert NMN into NAD+, a coenzyme involved in redox reactions and signaling.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Both can influence NAD+ pathways, but their structures, transport, and metabolism differ.
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.